http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Ohmachi, Ken (검색결과 1 건)
- 무료
- 기관 내 무료
- 유료
-
Ohmachi, Ken,Niitsu, Nozomi,Uchida, Toshiki,Kim, Seok Jin,Ando, Kiyoshi,Takahashi, Naoki,Takahashi, Naoto,Uike, Naokuni,Eom, Hyeon Seok,Chae, Yee Soo,Terauchi, Takashi,Tateishi, Ukihide,Tatsumi, Mitsu American Society for Clinical Oncology 2013 Journal of clinical oncology Vol.31 No.17
<P><B>Purpose</B></P><P>Effective and less aggressive therapies are required for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for or have undergone autologous stem-cell transplantation (ASCT). The present phase II study assessed the efficacy and safety of bendamustine plus rituximab (BR) in this population.</P><P><B>Patients and Methods</B></P><P>Patients with relapsed or refractory DLBCL treated with one to three prior chemotherapy regimens received rituximab 375 mg/m<SUP>2</SUP> intravenous (IV) infusion on day 1 and bendamustine 120 mg/m<SUP>2</SUP> by IV infusion on days 2 and 3 of each 21-day cycle for up to six cycles. The primary end point was overall response rate (ORR), and the secondary end points were complete response (CR) rate, progression-free survival (PFS), and safety.</P><P><B>Results</B></P><P>Sixty-three patients were enrolled, and 59 received BR. The median age was 67 years (range, 36 to 75 years), and 62.7% of patients were 65 years of age or older. Fifty-seven patients (96.6%) were previously treated with rituximab-containing chemotherapy. The ORR was 62.7% (95% CI, 49.1% to 75.0%), with a CR rate of 37.3% (95% CI, 25.0% to 50.9%). The ORRs were comparable between patients ≥ 65 years of age and less than 65 years (62.2% and 63.6%, respectively). The median PFS was 6.7 months (95% CI, 3.6 to 13.7 months). The most frequently observed grade 3 or 4 adverse events were hematologic: lymphopenia (78.0%), neutropenia (76.3%), leukopenia (72.9%), CD4 lymphopenia (66.1%), and thrombocytopenia (22.0%).</P><P><B>Conclusion</B></P><P>BR is a promising salvage regimen for patients with relapsed or refractory DLBCL after rituximab-containing chemotherapy, warranting further investigation.</P>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
